Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Oct 25, 2022 1:24pm
154 Views
Post# 35047270

RE:RE:RE:Slowdown in Covid-19 sales will further move Pfizer to M&A

RE:RE:RE:Slowdown in Covid-19 sales will further move Pfizer to M&AThe Global consulting companies PwC and EY have issued reports that Big Pharma has over $US1.25 Trillion in firepower and that Big Pharma's "sweet-spot" for small- medium size company M&A deals is between US$5 Billion and US$15 Billion ... so therefore a north of US$ 8 Billion deal expectation for the acquisition of ONCY is comfortably within the parameters of of Big Pharma's "sweet-spot", particularly since ONCY's pelareorep is a Platform Technology that can be used in multiple cancers in combination with multiple existing immuno-oncology therapies. 
<< Previous
Bullboard Posts
Next >>